Bicycle Therapeutics (BCYC) Total Current Liabilities (2018 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Total Current Liabilities came in at $47.6 million in Q2 2026, down 38.47% YoY from $77.4 million in Q2 2025, and down 2.56% on a QoQ basis from $48.9 million in Q1 2026.
Bicycle Therapeutics (BCYC) Total Current Liabilities (2018 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of Total Current Liabilities data on file, last reported at $47.6 million in Q2 2026.
- Quarterly Total Current Liabilities fell 38.47% year-over-year to $47.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $47.6 million (down 38.47% YoY) and the FY2025 annual result came in at $57.0 million, down 15.24% from the prior year.
- Total Current Liabilities slipped to $47.6 million in Q2 2026, from $48.9 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $77.4 million in Q2 2025 to a low of $35.4 million in Q1 2022.
- A 5-year average of $57.6 million and a median of $56.7 million in 2024 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities surged 77.64% — and 2026, when it plunged 38.47%.
- Tracing BCYC's Total Current Liabilities over 5 years: stood at $53.3 million in 2022, then surged by 30.36% to $69.5 million in 2023, then dropped by 3.32% to $67.2 million in 2024, then slipped by 15.24% to $57.0 million in 2025, then slipped by 16.41% to $47.6 million in 2026.
- The last three Total Current Liabilities figures came in at $47.6 million (Q2 2026), $48.9 million (Q1 2026), and $57.0 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - | 47.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 47.64 Mn |
| Mar 31, 2026 | 48.89 Mn |
| Dec 31, 2025 | 56.98 Mn |
| Sep 30, 2025 | 69.28 Mn |
| Jun 30, 2025 | 77.42 Mn |
| Mar 31, 2025 | 57.62 Mn |
| Dec 31, 2024 | 67.23 Mn |
| Sep 30, 2024 | 56.41 Mn |
| Jun 30, 2024 | 69.61 Mn |
| Mar 31, 2024 | 49.51 Mn |
| Dec 31, 2023 | 69.54 Mn |
| Sep 30, 2023 | 69.74 Mn |
| Jun 30, 2023 | 72.27 Mn |
| Mar 31, 2023 | 53.00 Mn |
| Dec 31, 2022 | 53.34 Mn |
| Sep 30, 2022 | 41.55 Mn |
| Jun 30, 2022 | 41.34 Mn |
| Mar 31, 2022 | 35.41 Mn |
| Dec 31, 2021 | 36.24 Mn |
| Sep 30, 2021 | 30.18 Mn |